A postgraduate research opportunity at the University of Otago.
- Academic background
- Sciences, Health Sciences
- Host campus
- Postgraduate Diploma, Honours, Master’s
- Pathology (Dunedin)
- Dr Glen Reid, Dr Cath Drummond
Mutant forms of the oncogene KRAS are common drivers of non-small cell lung cancers (NSCLC).
Recently, sotorasib and adagrasib – targeted agents that specifically inhibit the KRASG12C mutant – have been approved for treating patients. Unfortunately, while many respond to this therapy, resistance invariably occurs.
This project will investigate how variable KRAS expression levels in different subpopulations of NSCLC cells contribute to their initial survival when treated with KRAS inhibitors.